Abstract

Medication related osteonecrosis of the jaw (MRONJ) might lead morbidity that negatively affects the quality of life. MRONJ is mostly associated with antiresorptive bone treatments. Antiangiogenic treatments such as vascular endothelial growth factor (VEGF) targeted tyrosine kinase inhibitors also increase the risk of MRONJ, especially when combined with a bone-modifying agent (BMA). For the diagnosis of MRONJ; patient should have history of BMA or antiangiogenic treatments and no history of radiotherapy to jaw or metastasis.